2-bromo-1-(3-isopropoxy-4-methoxyphenyl)ethanone | 945612-58-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-1-(3-isopropoxy-4-methoxyphenyl)ethanone
• 英文别名: Ethanone, 2-bromo-1-[4-methoxy-3-(1-methylethoxy)phenyl]-；2-bromo-1-(4-methoxy-3-propan-2-yloxyphenyl)ethanone
• CAS: 945612-58-8
• 化学式: C₁₂H₁₅BrO₃
• 分子量: 287.153
• InChiKey: QQXPFRSHZAMRFR-UHFFFAOYSA-N

物化性质

• 沸点：
  348.5±27.0 °C(Predicted)
• 密度：
  1.332±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(3-isopropoxy-4-methoxyphenyl)ethanone 在 aluminum (III) chloride 、 sodium hydride 作用下， 以 二氯甲烷 、 N,N-二甲基苯胺 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 14.0h， 生成 2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)sulfanyl-1H-indol-2-yl]phenol
  参考文献：
  名称：

  Toward Highly Potent Cancer Agents by Modulating the C-2 Group of the Arylthioindole Class of Tubulin Polymerization Inhibitors

  摘要：

  New arylthioindole derivatives having different cyclic substituents at position 2 of the indole were synthesized as anticancer agents. Several compounds inhibited tubulin polymerization at submicromolar concentration and inhibited cell growth at low nanomolar concentrations. Compounds 18 and 57 were superior to the previously synthesized S. Compound 18 was exceptionally potent as an inhibitor of cell growth: it showed IC50 = 1.0 nM in MCF-7 cells, and it was uniformly active in the whole panel of cancer cells and superior to colchicine and combretastatin A-4. Compounds 18, 20, 55, and 57 were notably more potent than vinorelbine, vinblastine, and paclitaxel in the NCl/ADR-RES and Messa/Dx5 cell lines, which overexpress P-glycoprotein. Compounds 18 and 57 showed initial vascular disrupting effects in a tumor model of liver rhabdomyosarcomas at 15 mg/kg intravenous dosage. Derivative 18 showed water solubility and higher metabolic stability than 5 in human liver microsomes.

  DOI：

  10.1021/jm3013097
• 作为产物：
  描述：

  4-甲氧基-3-羟基苯乙酮 在 溴 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 2-bromo-1-(3-isopropoxy-4-methoxyphenyl)ethanone
  参考文献：
  名称：

  Toward Highly Potent Cancer Agents by Modulating the C-2 Group of the Arylthioindole Class of Tubulin Polymerization Inhibitors

  摘要：

  New arylthioindole derivatives having different cyclic substituents at position 2 of the indole were synthesized as anticancer agents. Several compounds inhibited tubulin polymerization at submicromolar concentration and inhibited cell growth at low nanomolar concentrations. Compounds 18 and 57 were superior to the previously synthesized S. Compound 18 was exceptionally potent as an inhibitor of cell growth: it showed IC50 = 1.0 nM in MCF-7 cells, and it was uniformly active in the whole panel of cancer cells and superior to colchicine and combretastatin A-4. Compounds 18, 20, 55, and 57 were notably more potent than vinorelbine, vinblastine, and paclitaxel in the NCl/ADR-RES and Messa/Dx5 cell lines, which overexpress P-glycoprotein. Compounds 18 and 57 showed initial vascular disrupting effects in a tumor model of liver rhabdomyosarcomas at 15 mg/kg intravenous dosage. Derivative 18 showed water solubility and higher metabolic stability than 5 in human liver microsomes.

  DOI：

  10.1021/jm3013097

文献信息

• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET UTILISATIONS DE CES DERNIERS
  申请人：YUMANITY THERAPEUTICS

  公开号：WO2018081167A1

  公开（公告）日：2018-05-03

  The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

  本发明涉及对神经系统疾病治疗中有用的化合物。本发明的化合物，单独或与其他药用活性剂结合，可用于治疗或预防神经系统疾病。
• Novel hybrids from lamellarin D and combretastatin A 4 as cytotoxic agents
  作者：Li Shen、Xiaochun Yang、Bo Yang、Qiaojun He、Yongzhou Hu

  DOI：10.1016/j.ejmech.2009.09.017

  日期：2010.1

  A new series of hybrids of lamellarin D and combretastatin A 4,1,2-diphenyl-5,6-dihydropyrrolo [2,1-a] isoquinolines, were designed as cytotoxic agents based on principles of combination in medicinal chemistry and taking the parent compounds' different anti-proliferative mechanisms into consideration. Twenty-two novel hybrids were synthesized through a convenient route, with a key step of core pyrrole formation and evaluated for their anti-proliferative activities in vitro against K-562, A-549, SMMC-7721, SGC-7901 and HCF-116 cancer cell lines. The results showed that some hybrids had good anti-proliferative activities in low IC50 ranges. (C) 2009 Elsevier Masson SAS. All rights reserved.
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET UTILISATIONS DE CES COMPOSÉS
  申请人：YUMANITY THERAPEUTICS

  公开号：WO2019018795A1

  公开（公告）日：2019-01-24

  The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
• Toward Highly Potent Cancer Agents by Modulating the C-2 Group of the Arylthioindole Class of Tubulin Polymerization Inhibitors
  作者：Giuseppe La Regina、Ruoli Bai、Whilelmina Maria Rensen、Erica Di Cesare、Antonio Coluccia、Francesco Piscitelli、Valeria Famiglini、Alessia Reggio、Marianna Nalli、Sveva Pelliccia、Eleonora Da Pozzo、Barbara Costa、Ilaria Granata、Amalia Porta、Bruno Maresca、Alessandra Soriani、Maria Luisa Iannitto、Angela Santoni、Junjie Li、Marlein Miranda Cona、Feng Chen、Yicheng Ni、Andrea Brancale、Giulio Dondio、Stefania Vultaggio、Mario Varasi、Ciro Mercurio、Claudia Martini、Ernest Hamel、Patrizia Lavia、Ettore Novellino、Romano Silvestri

  DOI：10.1021/jm3013097

  日期：2013.1.10

  New arylthioindole derivatives having different cyclic substituents at position 2 of the indole were synthesized as anticancer agents. Several compounds inhibited tubulin polymerization at submicromolar concentration and inhibited cell growth at low nanomolar concentrations. Compounds 18 and 57 were superior to the previously synthesized S. Compound 18 was exceptionally potent as an inhibitor of cell growth: it showed IC50 = 1.0 nM in MCF-7 cells, and it was uniformly active in the whole panel of cancer cells and superior to colchicine and combretastatin A-4. Compounds 18, 20, 55, and 57 were notably more potent than vinorelbine, vinblastine, and paclitaxel in the NCl/ADR-RES and Messa/Dx5 cell lines, which overexpress P-glycoprotein. Compounds 18 and 57 showed initial vascular disrupting effects in a tumor model of liver rhabdomyosarcomas at 15 mg/kg intravenous dosage. Derivative 18 showed water solubility and higher metabolic stability than 5 in human liver microsomes.